Hospitals received a 20% Medicare add-on for COVID patients treated with Remdesivir, potentially generating close to $100 million per 5,000 patients. Meanwhile, the WHO, NIH, and EMA recommended against ivermectin despite early promising meta-analyses showing potential mortality reduction. Hospitals went to court to prevent patients from receiving ivermectin even with a doctor's prescription. The financial architecture of COVID treatment protocols raised serious questions about whether profit drove treatment decisions.
“The financial incentive structure for hospitals created a system where the most expensive treatment was also the most profitable, while inexpensive alternatives were systematically excluded.”
From “crazy” to confirmed
The Claim Is Made
This is the moment they called it crazy.
When hospitals across America began treating COVID-19 patients in 2020, a financial incentive structure quietly took shape that few noticed at the time. The Centers for Medicare & Medicaid Services added a 20 percent bonus to the standard payment for any COVID patient treated with Remdesivir, an antiviral drug manufactured by Gilead Sciences. For a typical hospital handling thousands of infected patients, this policy could translate into nearly $100 million in additional revenue per 5,000 treated cases. The question that haunts this arrangement is simple: did financial architecture drive medical decisions?
The claim that emerged from patient advocates and independent researchers was direct and uncomfortable. They argued that while hospitals received substantial bonuses for using Remdesivir, cheaper alternatives showing promise in early research were simultaneously suppressed through official health channels. Specifically, ivermectin—a decades-old antiparasitic medication costing a fraction of Remdesivir—appeared in several meta-analyses suggesting potential mortality reduction benefits in COVID patients. Yet the World Health Organization, the National Institutes of Health, and the European Medicines Agency all recommended against its use outside clinical trials.
Official institutions dismissed these concerns as unfounded conspiracy thinking. Mainstream media largely echoed regulatory agencies in characterizing ivermectin as an "unproven horse paste," despite the fact that ivermectin for human use exists as a legitimate pharmaceutical product. Health authorities pointed to flawed studies and insisted that Remdesivir represented the evidence-based standard of care. The narrative was firm: trust the science, follow the protocols.
What documented evidence reveals, however, is more complicated than either the enthusiasts or dismissers acknowledged. The 20 percent Medicare bonus for Remdesivir is real and documented in CMS payment structures. The early meta-analyses suggesting ivermectin's potential are real and published in peer-reviewed journals, though many contained methodological limitations. What's also real is that hospitals literally went to court to prevent patients from receiving ivermectin even when prescribed by their own physicians. These were not marginal incidents but systematic legal barriers to treatment access.
Get the 5 biggest receipts every week, straight to your inbox — plus an exclusive PDF: The Top 10 Conspiracy Theories Proven True in 2025-2026. No spam. No agenda. Just the papers they couldn't hide.
You just read "Hospitals received massive financial bonuses for using Remde…". We send ones like this every week.
No one's said anything yet. Be the first to drop your take.
This is not to claim definitively that ivermectin was the cure that institutions suppressed, nor that Remdesivir was prescribed exclusively for profit. The evidence is more textured than that binary. It's to observe that a system was constructed where hospitals had direct financial incentives to use one drug while regulatory bodies simultaneously prevented access to another. Whether intentionally designed or emergently troubling, this alignment of financial incentives with medical monopoly on approved treatments created genuine cause for scrutiny.
The deeper damage is what this did to institutional credibility. People who noticed that Remdesivir payments exceeded the entire cost of ivermectin by orders of magnitude were not paranoid—they were reading CMS documents. When those same people were mocked rather than engaged, when legitimate questions about treatment protocols were dismissed as conspiracy, something fractured in the public's relationship with medical authority.
Trust in institutions requires not just being right, but appearing to be motivated by something other than profit. When financial incentives are structured to reward one treatment while regulations prevent alternatives, the appearance of propriety matters as much as the reality. What this episode demonstrated is that we built a system where it was nearly impossible to distinguish between sound medical judgment and sound financial judgment. That ambiguity, more than any single claim, is what demands our attention.
Beat the odds
This had a 0.7% chance of leaking — someone talked anyway.
Conspirators
~300Network
Secret kept
5.5 years
Time to 95% exposure
500+ years
